RxDoctor Payments Data

Calvin Hansen, MD

Neurology · Des Moines, IANPI 1639157373

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,107 of the $1,234 with a category attached, or 89.7%. 10 manufacturers reported payments, led by Biogen at 48.7% of the total. Reporting peaked in 2021 at $383 and has fallen 81.6% since, to $71 in 2025.

$1,234in general payments, 2019–2025

Across 31 payments — averaging $39.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$600
  • E.r. Squibb & Sons, L.L.C.$125
  • AbbVie$122
  • AstraZeneca$108
  • Genentech USA, Inc.$90
  • Novartis$89
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$1,10790%
  • Education$12710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 60th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$6,159
Medicare patients
50
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmpyraDalfampridine13$58,107
XcopriCenobamate16$17,074
Emgality PenGalcanezumab-Gnlm12$8,365
Dalfampridine ErDalfampridine45$4,540
Dimethyl Fumarate13$2,100
Baclofen43$751
Gabapentin29$552
AmantadineAmantadine Hcl12$216
Ropinirole Hcl12$143
Nortriptyline Hcl12$96

Paid to pharmacies, not to this prescriber.

Other neurology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →